On the other hand, a review of randomized controlled trials has reported that the use of different PARP inhibiting agents such as olaparib, niraparib, rucaparib, veliparib, and talazoparib significantly enhances the risk of AML/MDS in comparison to placebo (Kontandreopoulou et al., 2021). Here, PARP1 is linked to myelodysplastic syndrome.